Phase II Conjugation Reactions

Phase II Conjugation Reactions

Welcome to this module on Phase II conjugation reactions, a critical component of drug metabolism. While Phase I reactions (oxidation, reduction, hydrolysis) often introduce or expose polar functional groups, they frequently do not render the drug sufficiently hydrophilic for excretion. This is where Phase II reactions come into play. These reactions involve the covalent attachment of small, endogenous, polar molecules (conjugates) to the drug or its Phase I metabolite. This process significantly increases water solubility, making the compound more readily excretable via urine or bile, and generally leads to pharmacological inactivation. The enzymes responsible for Phase II reactions are collectively known as transferases, as they transfer a specific endogenous molecule to the xenobiotic. The most common and pharmacologically important Phase II reactions include glucuronidation, sulfation, acetylation, methylation, and glutathione conjugation. Each of these pathways utilizes a specific co-substrate that donates the conjugating moiety.

Key Phase II Conjugation Pathways

Glucuronidation

Glucuronidation is arguably the most common and quantitatively important Phase II pathway. It involves the transfer of glucuronic acid from the co-substrate uridine-5'-diphospho-alpha-D-glucuronic acid (UDPGA) to a suitable functional group on the drug or metabolite. This reaction is catalyzed by a family of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs are primarily located in the endoplasmic reticulum of hepatocytes but are also found in other tissues like the kidney, gut, and skin. Glucuronidation typically occurs at hydroxyl (-OH), carboxyl (-COOH), amino (-NH2), and sulfhydryl (-SH) groups, forming O-, N-, C-, or S-glucuronides, respectively. The resulting glucuronides are highly polar, negatively charged at physiological pH, and readily excreted. A classic example of a drug undergoing glucuronidation is paracetamol (acetaminophen). While a small portion is sulfated, glucuronidation is the major pathway for its detoxification. Drug-OH + UDPGA --(UGT)--> Drug-O-Glucuronide + UDP

Sulfation

Sulfation involves the transfer of a sulfonate group (SO3-) from the co-substrate 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to a hydroxyl or amino group on the xenobiotic. This reaction is catalyzed by sulfotransferases (SULTs), cytosolic enzymes primarily found in the liver, but also in the gut, kidney, and brain. Sulfation generally occurs on phenolic hydroxyl groups or primary and secondary amines. While glucuronidation often has a high-capacity, low-affinity profile, sulfation tends to be a low-capacity, high-affinity pathway, meaning it can be saturated at higher drug concentrations. Sulfate conjugates are also highly polar and readily excreted. Minoxidil, an antihypertensive and hair growth stimulant, undergoes sulfation to its active form, minoxidil sulfate. Drug-OH + PAPS --(SULT)--> Drug-O-Sulfate + PAP

Acetylation

Acetylation involves the transfer of an acetyl group from acetyl coenzyme A (acetyl-CoA) to a primary amine, hydrazine, or sulfonamide group. This reaction is catalyzed by N-acetyltransferases (NATs), which are cytosolic enzymes. NATs exhibit genetic polymorphism, leading to distinct "fast acetylator" and "slow acetylator" phenotypes in the population. This polymorphism has significant clinical implications for drugs like isoniazid, hydralazine, and procainamide, affecting their efficacy and toxicity profiles.

Methylation

Methylation involves the transfer of a methyl group from S-adenosylmethionine (SAM) to various functional groups, including hydroxyl, amino, and sulfhydryl groups. This reaction is catalyzed by methyltransferases (e.g., catechol-O-methyltransferase (COMT), thiopurine methyltransferase (TPMT)). Unlike most other Phase II reactions, methylation can sometimes decrease water solubility and may not always lead to inactivation. For instance, methylation of norepinephrine to epinephrine is an activation step.

Glutathione Conjugation

Glutathione (GSH) conjugation is a critical detoxification pathway, particularly for electrophilic compounds that can react with cellular macromolecules (e.g., DNA, proteins) and cause toxicity. This reaction involves the transfer of the tripeptide glutathione to electrophilic centers on the drug or its metabolite, forming a thioether linkage. The reaction is catalyzed by glutathione S-transferases (GSTs), a diverse family of enzymes found in the cytosol and microsomes. The resulting glutathione conjugate is then further metabolized through a series of steps (cleavage of glutamate and glycine, followed by N-acetylation of the cysteine moiety) to form a mercapturic acid, which is readily excreted in the urine or bile. The detoxification of reactive intermediates, such as the N-acetyl-p-benzoquinone imine (NAPQI) metabolite of paracetamol, is a prime example of the importance of glutathione conjugation. It's important to note that Phase I and Phase II reactions do not always occur sequentially. Some drugs can undergo Phase II reactions directly, while others may undergo multiple Phase I and Phase II reactions in various combinations. The interplay between these pathways determines the overall fate and elimination of a drug from the body.

Key Takeaways

Phase II reactions involve the covalent attachment of endogenous, polar molecules (conjugates) to drugs or their metabolites. These reactions primarily increase water solubility, facilitating excretion, and generally lead to pharmacological inactivation. Major Phase II pathways include glucuronidation (UGTs), sulfation (SULTs), acetylation (NATs), methylation (methyltransferases), and glutathione conjugation (GSTs). Each pathway utilizes a specific co-substrate (e.g., UDPGA for glucuronidation, PAPS for sulfation, acetyl-CoA for acetylation, SAM for methylation, GSH for glutathione conjugation). Genetic polymorphisms in Phase II enzymes (e.g., NATs) can lead to significant interindividual variability in drug metabolism and response. Glutathione conjugation is particularly important for detoxifying reactive electrophilic intermediates.

Practice Exercise

A new drug candidate, "Xenobiotica," is found to possess a phenolic hydroxyl group and a primary amine. Discuss the potential Phase II conjugation pathways Xenobiotica might undergo. For each pathway you identify, name the enzyme class involved, the co-substrate required, and briefly describe the likely impact on the drug's properties and subsequent elimination. Consider any potential interindividual variability that might be relevant.